News

As the 2nd International Glaucoma Symposium approaches in Mainz, Germany, Stephan Schulz highlights how the program bridges everyday clinical needs with the latest advances in AI, imaging, and surgery.

DTI-ALPS MRI tracks glymphatic flow changes in IIH, enabling noninvasive diagnosis and earlier protection against permanent vision loss.

Tenpoint Therapeutics’ YUVEZZI, expected in the US in Q2 2026, is the first fixed-dose combination drop designed to improve near vision via pupil modulation with once-daily dosing.

FDA feedback backs urcosimod’s Phase 2b/3 plan for neuropathic corneal pain, defining a meaningful pain endpoint in an unmet field.

Glaukos noted under the updated labeling, physicians may now re-administer iDose TR more than once in patients who maintain a healthy cornea, as defined by corneal endothelial cell density parameters.

Belite Bio completes enrollment in phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt disease type 1 (STGD1).

The trial is evaluating OPGx-MERTK gene therapy for MERTK-related retinitis pigmentosa (RP).

New research compares 7 HA dry eye drops; Ivizia and Thealoz Duo most closely match natural tear viscosity during blinking.

The trial will evaluate the safety and effectiveness of the company's titratable glaucoma therapy system, designed to optimize IOP reduction in patients undergoing glaucoma surgery.

AI reads infant retinal scans to flag lung disease early, while transient vision loss warns of looming stroke and heart events.

This enables the initiation of the EYETAC phase II clinical trial (NCT07285070) in patients with non-infectious anterior uveitis (NIAU).

From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua Mali, MD, FASRS, shares what he believes will define ophthalmology in the year ahead.

A study reveals that low-dose pilocarpine effectively reduces pupil size in presbyopic eyes with minimal impact on lens thickness and accommodation.

Optometrists track 2026 breakthroughs in dry eye therapies, AI-powered screening and referrals, and genetics-driven glaucoma risk tools that reshape patient care.

This one-day symposium on January 31, 2026, will bring together clinicians and experts at the University Eye Clinic in Mainz to discuss optic neuropathies and diagnostic trends.

The January 31, 2026, conference in Mainz, Germany, will focus on advances in optic neuropathy diagnosis, artificial intelligence applications, and surgical perspectives

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and sensitivity of the eyes, face, or head.

James Tsai, MD, MBA, sheds light on what is in the offing for glaucoma specialists

James Tsai, MD, MBA, discusses his approaches given the wide diversity of patients in a major urban setting when awareness of glaucoma can range from highly educated patients to uninformed individuals.

Data estimates the prevalence of glaucoma currently is almost 50% higher than previously estimated and over 1.6 million individuals in the UK are estimated to have glaucoma by 2060.

Japan fast-tracks MCO-010 optogenetic eye injection as studies show lasting safety and meaningful vision gains in inherited retinal disease.

The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Post‑Pfizer mRNA shots show short‑term corneal thickening and lower endothelial cell density, prompting closer monitoring for graft or low‑count patients.

Learn how multimodal imaging and complement inhibitors reshape geographic atrophy care, guiding early treatment, CNV monitoring, and AI-driven follow-up.

Analysis of 20 years of data highlights differences in reimbursement trends across ophthalmology subspecialties and practice settings, according to Dustin D. French, PhD.

Broadwood and Yunqi Capital will add 3 total members to the board, while the CEO and more step down.

A total of 38 patients were included in the study. All underwent implantation of the PRIMAretinal prosthetic chip with the goal of restoring vision.

The trial is evaluating OCU410 (AAV5-RORA) for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration.